Stéphane Culine - Concepedia

Author

Stéphane Culine

Hôpital Saint-Louis ORCID

Also Known As

Brigitte Duclos, Culine S, Culine, StÃ©phane, S Culine, S. Culine, Stephane CULINE, Stephane Culine, Stéphane Culine

264

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Hôpital Saint-Louis Institut Gustave Roussy Inserm Centre Léon Bérard Assistance Publique – Hôpitaux de Paris

About

Stéphane Culine is an author at Hôpital Saint-Louis specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	56	4.5K
2	Health Sciences	10	10	172
3	Biostatistics	4	4	171
4	Cell Biology	2	2	45
5	Public Health	1	1	97

Stéphane Culine

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Joaquim Bellmunt, Christine Théodore, T. Demkov, Journal of Clinical Oncology	2009	777
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly, European Urology UrologyGenitourinary CancerGetug-afu15 TrialMedicineAndrogen Deprivation Therapy	2015	454
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens Joaquim Bellmunt, Toni K. Choueiri, Ronan Fougeray, Journal of Clinical Oncology Prognostic FactorsUrologyPlatinum-refractory TccuGenitourinary CancerMedicine	2010	451
Abrogation of <i>De novo</i> Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice Vanessa Fritz, Zohra Benfodda, Geneviève Rodier, Molecular Cancer Therapeutics	2010	262
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Karim Fizazi, Laura Faivre, F. Lesaunier, The Lancet Oncology UrologyGetug 12Genitourinary CancerMedicineAndrogen Deprivation Therapy	2015	236
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer Evan Y. Yu, George Wilding, Edwin M. Posadas, Clinical Cancer Research	2009	218
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial Karim Fizazi, Lance C. Pagliaro, Agnès Laplanche, The Lancet Oncology UrologyMedicineCancer ManagementPathologyTumour Marker Decline	2014	197
miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice Cyrielle Clapé, Vanessa Fritz, Corinne Henriquet, PLoS ONE	2009	196
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Stéphane Culine, Christine Théodore, Maria De Santis, British Journal of Cancer	2006	186

Page 1